<![CDATA[Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) remain global health challenges, with long-term adherence to antiretroviral therapy (ART) as a major barrier to effective management. This study aims to analyze the impact of digital technology on HIV treatment adherence through three pharmaceutical perspectives pharmacoeconomics, social pharmacy, and pharmacoepidemiology to develop a comprehensive and evidence-based evaluation framework. A narrative review approach was employed by systematically reviewing literature from international and national databases (PubMed, Scopus, ScienceDirect, Google Scholar) between 2015 and 2025. Findings reveal that digital interventions such as mHealth, telemedicine, chatbots, and SMS reminders are cost-effective, ICERs ranging from US$864 to US$1,037 per QALY and potential cost savings of 15–20% per patient annually. Socially, these technologies improve adherence by 25–30%, reduce stigma, and enhance patient empowerment, though digital literacy gaps and infrastructure limitations persist. From a pharmacoepidemiological perspective, digital tools contribute to sustained viral load suppression, increased CD4+ counts, and reduced drug resistance risk. The study underscores the importance of an integrative and hybrid implementation model that combines digital solutions with pharmacist-led support and community engagement. In conclusion, the integration of digital technology in HIV management enhances clinical outcomes, economic efficiency, and social equity, advancing the global UNAIDS 95-95-95 targets toward ending the AIDS epidemic by 2030.Keywords: HIV, Digital Technology, Pharmacoeconomics, Social Pharmacy, Pharmacoepidemiology, Adherence ]]>
Copyrights © 2026
